Genenta Science S.p.A. (SAEN)
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Aerospace & Defense
Genenta Science S.p.A.
Trials need funding. See this company's dilution risk and cash position.
- Phase 1/2Terminated
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Temferon
Glioblastoma Multiforme
NCT03866109Enrollment25StartMar 2019Primary CompletionMay 2026CompletionMay 2026 - Phase 1/2Terminated
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Temferon
Multiple Myeloma
NCT03875495Enrollment9StartMar 2019Primary CompletionApr 2021CompletionApr 2021 - Phase 1/2Terminated
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
Pembrolizumab, Cabozantinib
Clear Cell RCC
NCT06716853Enrollment10StartOct 2024Primary CompletionJan 2026CompletionJan 2026
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1/2 | Terminated | Temferon | NCT03866109 |
| Phase 1/2 | Terminated | Temferon | NCT03875495 |
| Phase 1/2 | Terminated | Pembrolizumab, Cabozantinib | NCT06716853 |